BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17228863)

  • 1. Stereoselectivity by enantiomeric inhibitors of matrix metalloproteinase-8: new insights from molecular dynamics simulations.
    Aschi M; Besker N; Re N; Pochetti G; Coletti C; Gallina C; Mazza F
    J Med Chem; 2007 Jan; 50(2):211-8. PubMed ID: 17228863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates.
    Pochetti G; Gavuzzo E; Campestre C; Agamennone M; Tortorella P; Consalvi V; Gallina C; Hiller O; Tschesche H; Tucker PA; Mazza F
    J Med Chem; 2006 Feb; 49(3):923-31. PubMed ID: 16451058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of new tripeptide phosphonate inhibitors of MMP-8 and MMP-2.
    Agamennone M; Campestre C; Preziuso S; Consalvi V; Crucianelli M; Mazza F; Politi V; Ragno R; Tortorella P; Gallina C
    Eur J Med Chem; 2005 Mar; 40(3):271-9. PubMed ID: 15725496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP-8).
    Pochetti G; Montanari R; Gege C; Chevrier C; Taveras AG; Mazza F
    J Med Chem; 2009 Feb; 52(4):1040-9. PubMed ID: 19173605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.
    Tuccinardi T; Martinelli A; Nuti E; Carelli P; Balzano F; Uccello-Barretta G; Murphy G; Rossello A
    Bioorg Med Chem; 2006 Jun; 14(12):4260-76. PubMed ID: 16483784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QSAR-by-NMR: quantitative insights into structural determinants for binding affinity by analysis of 1H/15N chemical shift differences in MMP-3 ligands.
    Matter H; Schudok M; Elshorst B; Jacobs DM; Saxena K; Kogler H
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1779-83. PubMed ID: 15780605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.
    Kiyama R; Tamura Y; Watanabe F; Tsuzuki H; Ohtani M; Yodo M
    J Med Chem; 1999 May; 42(10):1723-38. PubMed ID: 10346925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8.
    Campestre C; Agamennone M; Tortorella P; Preziuso S; Biasone A; Gavuzzo E; Pochetti G; Mazza F; Hiller O; Tschesche H; Consalvi V; Gallina C
    Bioorg Med Chem Lett; 2006 Jan; 16(1):20-4. PubMed ID: 16242329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMR solution structure of the catalytic fragment of human fibroblast collagenase complexed with a sulfonamide derivative of a hydroxamic acid compound.
    Moy FJ; Chanda PK; Chen JM; Cosmi S; Edris W; Skotnicki JS; Wilhelm J; Powers R
    Biochemistry; 1999 Jun; 38(22):7085-96. PubMed ID: 10353819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QSAR analysis of some 5-amino-2-mercapto-1,3,4-thiadiazole based inhibitors of matrix metalloproteinases and bacterial collagenase.
    Jamloki A; Karthikeyan C; Hari Narayana Moorthy NS; Trivedi P
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3847-54. PubMed ID: 16682189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of phosphinate and phosphonate inhibitors to aspartic proteases: a first-principles study.
    Vidossich P; Carloni P
    J Phys Chem B; 2006 Jan; 110(3):1437-42. PubMed ID: 16471695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of dog and human gastric lipases by enantiomeric phosphonate inhibitors: a structure-activity study.
    Miled N; Roussel A; Bussetta C; Berti-Dupuis L; Rivière M; Buono G; Verger R; Cambillau C; Canaan S
    Biochemistry; 2003 Oct; 42(40):11587-93. PubMed ID: 14529268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity.
    Pavlovsky AG; Williams MG; Ye QZ; Ortwine DF; Purchase CF; White AD; Dhanaraj V; Roth BD; Johnson LL; Hupe D; Humblet C; Blundell TL
    Protein Sci; 1999 Jul; 8(7):1455-62. PubMed ID: 10422833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
    Cheng XC; Wang Q; Fang H; Tang W; Xu WF
    Bioorg Med Chem; 2008 May; 16(10):5398-404. PubMed ID: 18440232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding preferences of hydroxamate inhibitors of the matrix metalloproteinase human fibroblast collagenase.
    Toba S; Damodaran KV; Merz KM
    J Med Chem; 1999 Apr; 42(7):1225-34. PubMed ID: 10197966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereoselectivity of binding of alpha-(N-benzylamino)benzylphosphonic acids to prostatic acid phosphatase.
    Vovk AI; Mischenko IM; Tanchuk VY; Kachkovskii GA; Sheiko SY; Kolodyazhnyi OI; Kukhar VP
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4620-3. PubMed ID: 18672366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors.
    Heim-Riether A; Taylor SJ; Liang S; Gao DA; Xiong Z; Michael August E; Collins BK; Farmer BT; Haverty K; Hill-Drzewi M; Junker HD; Mariana Margarit S; Moss N; Neumann T; Proudfoot JR; Keenan LS; Sekul R; Zhang Q; Li J; Farrow NA
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5321-4. PubMed ID: 19692239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular modeling of binding between amidinobenzisothiazoles, with antidegenerative activity on cartilage, and matrix metalloproteinase-3.
    Amadasi A; Cozzini P; Incerti M; Duce E; Fisicaro E; Vicini P
    Bioorg Med Chem; 2007 Feb; 15(3):1420-9. PubMed ID: 17113299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereoselective binding of an enantiomeric pair of stromelysin-1 inhibitors caused by conformational entropy factors.
    Parker MH; Ortwine DF; O'Brien PM; Lunney EA; Banotai CA; Mueller WT; McConnell P; Brouillette CG
    Bioorg Med Chem Lett; 2000 Nov; 10(21):2427-30. PubMed ID: 11078193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.
    O'Brien PM; Ortwine DF; Pavlovsky AG; Picard JA; Sliskovic DR; Roth BD; Dyer RD; Johnson LL; Man CF; Hallak H
    J Med Chem; 2000 Jan; 43(2):156-66. PubMed ID: 10649971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.